[Monotherapy, empirical and targetted, with imipenem-cilastatin in sepsis of bacterial origin].
The authors describe an open study in 22 patients with febrile conditions of unknown origin who were treated with imipenem-cilastatin while waiting for routine laboratory and culture tests. These were done immediately at the patients' entry into hospital, after which imipenem-cilastatin treatment was started immediately, and was subsequently confirmed by the isolates and culture tests. The drug was found to be active and to eradicate the responsible organism in all cases. In addition, it was found to be easy to handle and not to give rise to side-effects or changes in laboratory tests.
Fiorentino
F
F
De Sena
R
R
Manzillo
E
E
Iadanza
A
A
Conte
M
M
Coppola
M G
MG
Galderisi
P
P
Postiglione
A
A
Arciello
M T
MT
Covelli
B
B
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D015377:Cilastatin / Q000627:therapeutic use*; D000077728:Cilastatin, Imipenem Drug Combination; D004338:Drug Combinations / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D005335:Fever of Unknown Origin / Q000188:drug therapy*; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D015377:Cilastatin; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination
La monoterapia, empirica e mirata, con imipenem-cilastatina nelle sepsi ad eziologia batterica.